Dr. Hurvitz on Toxicity Associated With Neratinib in HER2+ Breast Cancer

Video

In Partnership With:

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses toxicity associated with neratinib in the treatment of patients with HER2-positive breast cancer.

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center, discusses toxicity associated with neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.

Specifically, diarrhea is a concern in patients treated with this oral TKI, says Hurvitz. In the ExteNET study, the trial which evaluated the use of neratinib after trastuzumab (Herceptin)-based adjuvant therapy in patients with HER2-positive disease who were healthier in general, about 40% of patients developed grade 3 diarrhea. Hurvitz notes that grade 3 diarrhea is particularly crippling—this translates to about 7 bowel movements over a normal number on a given day. Incontinence, IV fluid hydration, and hospitalization should be considered when patients demonstrate signs of severe diarrhea, she adds.

With that being said, clinicians appear to be getting better at managing this toxicity. As long as patients are educated, and upfront loperamide is used for all patients when they initiate neratinib therapy with very close clinical follow-up, this toxicity can be managed.

Furthermore, investigators at UCLA participated in the phase II CONTROL trial which focused solely on the management of neratinib-associated diarrhea. In that study, investigators utilized combinations of loperamide (Imodium) and budesonide or colestipol. With the help of these agents, grade 3 diarrhea rates were reduced to about 10%, Hurvitz says.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute